ImmuCell Corporation

US$9.80As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ICCCHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 5.76%
Div yield —
ROE 2.57%
Biotechnology
Beta (5Y) 0.62
PE TTM 131.4
TSR TTM 57.07%
Mkt cap US$89.01M
ROIC 12.29%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$9.85
0.54%
(45.65%)
Hold 5|4|1|5|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.11
0.11
0.12
0.13
20.29%
21.81%
21.23%
17.73%
Revenue$M
4.094
4.187
4.107
4.219
0.68%
4.38%
1.91%
2.36%
Peers (US$89.01M)
Cap (US$)
PE
87.97M
—
88.97M
—
Capital
TTM
5Y
10Y
Leveragex
7.600
(2.648)
(1.827)
EBIT/Intx
0.274
0.201
0.165
Own earn%
234.62
(53.60)
(64.39)
Sh yield%
48.88
1.90
5.39
Owners
Insiders/Inst%
13.82
76.09
Short interest%
3.51
SBC / revenue%
5.43
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
17–23
$1 testx
—
Incr. ROIC%
2